Sphingosine-1-phosphate receptor signalling in the heart [PDF]
Cardiovascular Research, 2008 The five known members of the sphingosine-1-phosphate (S1P) receptor family exhibit diverse tissue expression profiles and couple to distinct G-protein-mediated signalling pathways. S1P1, S1P2, and S1P3 receptors are all present in the heart, but the ratio of these subtypes differs for various cardiac cells. The goal of this review is to summarize data
Christopher K, Means, Joan Heller, Brown
openaire +2 more sources
Frontiers in Physiology, 2018 Platelets affect myocardial damage from ischemia/reperfusion. Redox-dependent sphingosine-1-phosphate production and release are altered in diabetic platelets. Sphingosine-1-phosphate is a double-edged sword for ischemia/reperfusion injury. Therefore, we
Isabella Russo +12 more
doaj +1 more source
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. [PDF]
, 2014 BackgroundFTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis.
Blanc, Caroline A +2 more
core +1 more source
Sphingosine kinase 1 in breast cancer: A new molecular marker and a therapy target [PDF]
, 2020 It is now well-established that sphingosine kinase 1 (SK1) plays a significant role in breast cancer development, progression, and spread, whereas SK1 knockdown can reverse these processes.
Alshaker, Heba +2 more
core +1 more source
Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury. [PDF]
, 2006 Activated protein C (APC) has emerged as a novel therapeutic agent for use in selected patients with severe sepsis, even though the mechanism of its benefit is not well established.
Looney, Mark R, Matthay, Michael A
core +2 more sources
Glucocorticoids for human skin: New aspects of the mechanism of action [PDF]
, 2005 Topical glucocorticoids have always been considered first-line drugs for inflammatory diseases of the skin and bronchial system. Applied systemically, glucocorticoids are used for severe inflammatory and immunological diseases and the inhibition of ...
Ahmed, M. +4 more
core +1 more source
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery [PDF]
Biomolecules & Therapeutics, 2017 Initial discovery on sphingosine 1-phosphate (S1P) as an intracellular second messenger was faced unexpectedly with roles of S1P as a first messenger, which subsequently resulted in cloning of its G protein-coupled receptors, S1P₁₋₅. The molecular identification of S1P receptors opened up a new avenue for pathophysiological research on this lipid ...
Park, Soo-Jin, Im, Dong-Soon
openaire +2 more sources
Acta Pharmaceutica Sinica B, 2023 Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2–3 years and there is no effective intervention to treat IPF other than ...
Mengyao Hao +15 more
doaj +1 more source
Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes. [PDF]
, 2019 Wilson disease (WD) is a genetic copper overload condition characterized by hepatic and neuropsychiatric symptoms with a not well-understood pathogenesis.
Czlonkowska, Anna +6 more
core +2 more sources
Structure of the First Sphingosine 1-Phosphate Receptor [PDF]
Science Signaling, 2012 The lipid sphingosine 1-phosphate may laterally diffuse through the membrane to bind a receptor.
Abby L, Parrill +2 more
openaire +2 more sources